SEC Comment Letter 0000000000-26-005256 to CNS Pharmaceuticals, Inc. (CNSP)
CNS Pharmaceuticals, Inc.
Date: May 22, 2026 · CIK: 0001729427 · Accession: 0000000000-26-005256
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-296033
Letter
May 22, 2026 Steve O’Loughlin Chief Financial Officer CNS Pharmaceuticals, Inc. 1717 K Street, NW Washington, DC 20006 Re: CNS Pharmaceuticals, Inc. Registration Statement on Form S-3 Filed May 19, 2026 File No. 333-296033 Dear Steve O’Loughlin: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jimmy McNamara at 202-551-7349 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Cavas S. Pavri
Show Raw Text
May 22, 2026 Steve O’Loughlin Chief Financial Officer CNS Pharmaceuticals, Inc. 1717 K Street, NW Washington, DC 20006 Re: CNS Pharmaceuticals, Inc. Registration Statement on Form S-3 Filed May 19, 2026 File No. 333-296033 Dear Steve O’Loughlin: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jimmy McNamara at 202-551-7349 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Cavas S. Pavri